About UsAbout UsServicesProductsNews & EventsContact Us
About Us

Services

ProductsPublicationsTestimonials

News & Events

Contact Us

A Strategic Assessment of Cardiovascular Innovations

The objective of this report, issued March 1999, is to identify, critique, and rate emerging cardiovascular products available for in-licensing. The analyses are fresh and discriminating - both the merits and the pitfalls of each product have been stringently reviewed against a number of relevant criteria embracing both product (e.g., mode of action) and company source (e.g., management, pipeline). In the final analysis, readers will be uniquely positioned to act quickly on expanding or launching their cardiovascular product line.

Table of Contents

List of Figures and Tables
Preface
Expert Contributors
I. Action Report
II. Executive Summary
III. Introduction
IV. Market Dynamics
V. Report Methodology

Cardiovascular Diseases/Disorders

VI. Acute Coronary Syndromes
VII. Acute Myocardial Infarction (AMI)
VIII. Congestive Heart Failure
IX. Diabetes
X. Hyperlipidemia
XI. Hypertension
XII. Interventional Cardiology
XIII. Obesity
XIV. Stroke

Novel Platforms

XV. ACAT Inhibitors (Hyperlipidemia)
XVI. Aldose Reductase Inhibitors (Diabetes)
XVII. Angiogenesis (End-stage Coronary Artery/peripheral Vascular Disease)
XVIII. Angiotensin II Receptor Inhibitors (Hypertension and CHF)
XIX. Echocardiographic Imaging Agents (Heart Disease)
XX. Endothelin Receptor Antagonists (AMI and CHF)
XXI. Intravascular Brachytherapy (Angioplasty)
XXII. Neuronal Transplants (Stroke)
XXIII. Neuronal Nitric Oxide Synthase Inhibitors (Stroke)
XXIV. Neuropeptide Y Inhibitors (Obesity)
XXV. Oral GPIIb/IIIa Inhibitors (Acute Coronary Syndromes)
XXVI. Conclusion

Cardiovascular Panelists

Roland Greenberg, Ph.D.
President and CEO
Troy Technology Consulting, Inc.

Thomas H. Keller, Jr.
Principal
Keller & Associates

Colin G. Nichols, Ph.D.
Associate Professor of Cell Biology and Physiology
Washington University School of Medicine

Ronald N. Riner, M.D.
President and CEO
The Riner Group, Inc.

H. William Strauss, M.D.
Chairman of Nuclear Medicine
Stanford University School of Medicine

Cardiovascular Editorial Board

Lewis Becker, M.D.
Cardiologist
John Hopkins University School of Medicine

Alan Yeung, M.D.
Assistant Professor
Director of Cardiac Catheterization and Interventional Laboratories
Stanford University School of Medicine

Barry Zaret, M.D.
Chief of Cardiology
Yale University School of Medicine

© 2017 BeckerPharmaceuticals. All Rights Reserved.